Local Control With Reduced-Dose Radiotherapy for Low-Risk Rhabdomyosarcoma: A Report From the Children’s Oncology Group D9602 Study
John C. Breneman(University of Cincinnati), Douglas S. Hawkins(Seattle Children's Hospital), Sarah S. Donaldson(Stanford University), Jeff M. Michalski(Washington University in St. Louis), David A. Rodeberg(East Carolina University), R. Beverly Raney(The University of Texas MD Anderson Cancer Center), Suzanne L. Wolden(Memorial Sloan Kettering Cancer Center), David Walterhouse(Children's Hospital of Philadelphia), Fran Laurie(University of Massachusetts Chan Medical School), Jane L. Meza(Children's Oncology Group), William H. Meyer(Lawrence Livermore National Laboratory)
International Journal of Radiation Oncology*Biology*Physics
November 20, 2011
Cited by 78
Related Papers
Comprehensive Genomic Analysis of Rhabdomyosarcoma Reveals a Landscape of Alterations Affecting a Common Genetic Axis in Fusion-Positive and Fusion-Negative Tumors
|Cancer Discovery|2014|789
Survival and prognosis with osteosarcoma: outcomes in more than 2000 patients in the EURAMOS-1 (European and American Osteosarcoma Study) cohort
|European Journal of Cancer|2019|724
Proton FLASH Radiotherapy for the Treatment of Symptomatic Bone Metastases
|JAMA Oncology|2022|557
Comparison of MAPIE versus MAP in patients with a poor response to preoperative chemotherapy for newly diagnosed high-grade osteosarcoma (EURAMOS-1): an open-label, international, randomised controlled trial
|The Lancet Oncology|2016|537
Long-Term Outcomes Among Adult Survivors of Childhood Central Nervous System Malignancies in the Childhood Cancer Survivor Study
|JNCI Journal of the National Cancer Institute|2009|530